Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential
Management Reshuffle And 20% Headcount Cut
Executive Summary
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.
You may also be interested in...
Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
UK Firms Big And Small Benefit From Biotech Bubble
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut
Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.